Frankfurt
08.01.26 | 08:08
0,146 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12.25 | AlzeCure Pharma: AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease | 312 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system... ► Artikel lesen | |
| 11.11.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2025 | 246 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 14.10.25 | AlzeCure Pharma: Response Letter to Previous Article Published about Alzstatin's Unique Mode of Action Against Alzheimer's | 584 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| 08.09.25 | AlzeCure Pharma: Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025 | 310 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 04.09.25 | AlzeCure Pharma: Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference | 340 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 4, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 26.08.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2025 | 374 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 26, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - June 2025 is now available on the company's... ► Artikel lesen | |
| 20.08.25 | AlzeCure Pharma: AlzeCure Appoints Cecilia Wadell as New Head of Development | 424 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 19.08.25 | AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs | 404 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 19, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 11.08.25 | New last trading day for paid subscription shares (BTA) of AlzeCure Pharma AB | 288 | GlobeNewswire | At the request of AlzeCure Pharma AB, the last trading day in AlzeCure Pharma AB's paid subscription shares will be changed from 2025-08-14 to 2025-08-13.
Instrument:
Paid subscription... ► Artikel lesen | |
| 05.08.25 | AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference | 425 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 29.07.25 | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 524 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 24.07.25 | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option | 385 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 23.07.25 | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed According to Preliminary Results | 347 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 21.07.25 | AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference | 378 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 16.07.25 | AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue | 336 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 15.07.25 | AlzeCure Pharma: AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA | 395 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.07.25 | The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares | 423 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - At an extraordinary general meeting in AlzeCure Pharma AB on July 2, 2025, the shareholders decided to approve... ► Artikel lesen | |
| 02.07.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 402 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 17.06.25 | AlzeCure Pharma: AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue | 420 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 16.06.25 | Notice To Extraordinary General Meeting In Alzecure Pharma AB | 394 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 403,75 | -2,58 % | $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today | ||
| VIATRIS | 10,885 | +2,06 % | Viatris Inc.: Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer | PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris'... ► Artikel lesen | |
| ALTIMMUNE | 3,520 | -1,79 % | Altimmune, Inc: Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today... ► Artikel lesen | |
| OPKO HEALTH | 1,152 | -1,42 % | OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth | ||
| JAGUAR HEALTH | 1,080 | 0,00 % | Jaguar Health, Inc.: Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication | Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,385 | -2,31 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| AURINIA PHARMACEUTICALS | 13,100 | -4,06 % | Wachstumssorgen: Leerink Partners stuft Aurinia Pharmaceuticals herab | ||
| KIORA PHARMACEUTICALS | 2,185 | -0,23 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds | Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263)... ► Artikel lesen | |
| LIPOCINE | 7,530 | +0,07 % | Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
Topline results on track for the second quarter of 2026
SALT LAKE CITY... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,238 | -2,65 % | Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target | ||
| PHOTOCURE | 6,410 | +2,72 % | Photocure: The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison | OSLO, Norway, Dec. 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 23,800 | -3,64 % | ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio... ► Artikel lesen | |
| MEDICURE | 0,695 | +1,46 % | Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025 | WINNIPEG, MB / ACCESS Newswire / November 19, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 39,535 | +3,12 % | Achtung Anschnallen! 2026 wird zum Raketen-Start für Novo Nordisk, Evotec, Bayer und Vidac Pharma | Die Börse startet mit guter Laune ins neue Jahr 2026. Dass man nicht nur mit Tech-Aktien Geld verdienen kann, zeigte der Minen- und Rohstoffsektor, wo sich nahezu jeder Wert verdoppeln konnte und auch... ► Artikel lesen | |
| MERCK KGAA | 127,70 | +0,27 % | Merck KGaA: Weichenstellung zum Jahresstart? | 2025 war ein ungewöhnliches Jahr für den deutschen Aktienmarkt: In einige Aktien wurden extrem positive Erwartungen eingepreist, in andere nahezu ein Worst-Case-Szenario. Die Merck KGaA-Aktie gehört... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,146 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.